Navigation Links
Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
Date:6/26/2012

FARMINGTON, Conn., June 26, 2012 /PRNewswire-iReach/ -- As the global economy recovers from recession, the drug discovery industry – which weathered the downturn better than most – are poised for a significant period of new growth. To make the most of this surge in business and make better business decisions, companies need the best, most accurate market data available. Global Information, Inc. is pleased to announce a slate of new drug discovery market forecasts and pipeline assessments from partner publishing firm GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20120626/CG31054)

Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The pain management market is ripe with immediate opportunities particularly for reformulations and the generics segment. The looming patent cliff means that generic competition will become increasingly relevant as the current market leaders go off patents. This report provides analyses of key recent licensing and partnership agreements in the acute pain therapeutics market. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications. Product profiles are included for the following major marketed products in the acute pain therapeutics market: Celebrex, DepoDur, Ofirmev, Oxecta, Nucynta, Dilaudid, Sprix, Zipsor, Flector Patch and Vicoprofen.

Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Tentative approval from the FDA for generic version of Cymbalta (duloxetine) is on the horizon. The generic market for Cymbalta will be hotly contested despite a U.S. District Court- issued order prohibiting sale of generic duloxetine prior to patent expiry in June 2013. What's the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? - Identify, understand and capitalize by reading this new report.

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Bayer recently announced trials of blockbuster Regorafenib have showed promise against gastrointestinal cancer. The German drugmaker added that it will seek approval for wider use of Regorafenib. This report includes molecule profiles for Regorafenib (BAY 73-4506) as well as other late-stage molecules under clinical development including Mastinib, Nexavar (sorafenib) and Tasigna (nilotinib). Clinical trial mapping for gastrointestinal stromal tumors therapeutics is also provided by country, by phase, by trial status, by prominent sponsors and by companies.

Infectious Immunology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Rising demand for hepatitis and HIV testing is set to increase the value of the infectious immunology market. The global infectious immunology market is projected to grow at a CAGR of 7.3% through 2018. The US currently ranks as the largest market for infectious immunology testing with nearly 36% of global revenue. Large testing volumes, high public awareness and reimbursement availability are significant factors contributing to the US infectious immunology testing market. Infectious immunology markets of emerging nations are small relative to developed countries, but they have witnessed the highest growth rates in the past decade. China's infectious immunology market is expected reach revenues close to a billion dollars while the market in India is forecast to reach revenues of nearly $200 million by 2018.

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

Millions of Americans have hepatitis, but most don't know it. The market for preventative vaccines like Havrix, Vaqta, Twinrix, Ambirix, Avaxim and Epaxal from GlaxoSmithKline, Merck & Co, and Crucell are working to reduce the number of hepatitis contractions worldwide. This report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market.

Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The traumatic brain injury therapeutics market was valued at $1.25 billion in 2011 and is expected to rise at a compound annual growth rate of 2.8% reaching $1.55 billion by 2019. Traumatic brain injury (TBI) is a major cause of death and disability. An estimated 5.3 million people are living with a permanent TBI-related disability in the U.S. while a third of all injury related deaths are attributed to traumatic brain injury.

Post Traumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019

An essential source of information and analysis that identifies key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report provides valuable insights on pipeline products, the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The gout space is heating up, but is there sufficient room in the market to accommodate multiple new therapeutics? Major marketed classes of products for treatment of gout include NSAIDs, corticosteroids, Colcrys (Colchicines), Allopurinol, Probenecid, Uloric, Adenuric (febuxostat) and Krystexxa (Pegloticase). In recent news, new analysis of phase III trials showed gout patients with chronic kidney disease responding to Krystexxa. Earlier this month Takeda Pharmaceuticals announced the completion of its acquisition of URL Pharma which will add Colcrys (colchicine) to Takeda's gout treatment portfolio moving forward.

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The number of methicillin-resistant staphylococcus aureus (MSRA) infection cases appears to be declining nationwide according to the most recent data release by the U.S. Department of Health and Human Services. In 2005, for every 100,000 people nearly 36 individuals contracted MSRA infections. That number has declined to 21 in 2010. The U.S. government aims to keep infection rates down to 13 per 100,000 people by 2013. This report provides profiles of the most promising drugs used to treat MSRA infections such as Torezolid phosphate (TR-701, Tedizolid), Ceftobiprole Medocaril, Dalbavancin and Oritavancin.

Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market in future. Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.

About Global Information, Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world.

Media Contact: Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces the continuation of its strategic partnership with and platinum sponsorship of Global ... in the safe and effective management of complex spine deformity cases, particularly in ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Michael Vick ... and transforming the quarterback position. The former overall number one pick in the 2001 ... football career. He holds the record for the most career rushing yards by a ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As part of ... today to honor the victims of the Holocaust and Nazi persecution, Center for ... Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next week. ...
(Date:4/24/2017)... ... ... Pink , a national non-profit organization focusing on the prevention and early detection of breast ... proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay ... the Board and launched a national search to find a visionary new leader to grow ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):